ArticleAACE endocrinology and diabetes
Management of Triiodothyronine (T3)-Predominant Graves' Disease in Pregnancy: A Case Series.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Graves' disease (GD) in pregnancy requires the careful titration of antithyroid drugs and close monitoring to avoid maternal, fetal and neonatal complications. GD can occasionally be triiodothyronine (T3)-predominant, with normal or low free thyroxine (fT4) despite high free T3 (fT3) and suppressed thyroid-stimulating hormone levels. While guidelines advocate keeping the fT4 at or just above the upper limit of normal (ULN) in conventional GD in pregnancy, there is little literature on the optimal management for T3-predominant GD in pregnancy. Case Report: We describe 3 pregnancies (2 patients age 23 and 32) with T3-predominant GD in pregnancy treated with propylthiouracil titrated to aim fT3 at or slightly above ULN with good outcomes. fT4 of these patients were occasionally low or low-normal, which is controversial as the fetus is deemed dependent on maternal fT4 (not fT3) especially in the first trimester for development. However, allowing fT4 to be at or slightly above ULN would entail very high fT3 levels and severe maternal hyperthyroidism. There were no signs of fetal hypothyroidism or hyperthyroidism during the pregnancies. In all 3 pregnancies, they delivered at term via normal vaginal delivery. One neonate had mild thyrotoxicosis not requiring treatment which resolved within a few weeks, and the other 2 neonates were euthyroid. No other complications were observed. Discussion: We discuss the pathophysiology and considerations behind our approach. Conclusion: Aiming for fT3 (instead of fT4) at or slightly above ULN to avoid maternal overt hyperthyroidism appears to be a reasonable approach that physicians can consider when treating T3-predominant GD in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.